Coherus Biosciences | CHRS - Operating Expenses


Coherus Biosciences reported $51.83M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 5.69B 6B Sep/2026
Baxter International USD 6.5B 3.82B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Fujifilm JPY 795.04B 19.73B Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Merck USD 10.75B 5.02B Sep/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Pacira USD 1.18B 995.96M Sep/2026
Perrigo USD 961.4M 670.9M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026
Zoetis USD 3.3B 155M Sep/2026